Pneumotox » Drug » CAR T-cell therapy

CAR T-cell therapy

4

Last update : 08/02/2022

I.ao Pulmonary infiltrates

1

II.a Pulmonary edema, noncardiogenic (NCPE)

2

II.b ARDS - Acute lung injury

1

II.r Interstitial pulmonary edema

1

III.c Hemoptysis

1

V.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

1

X.an Cytokine release syndrome - Cytokine storm

4

XII.a Left or biventricular dysfunction/failure

1

XII.af Coronary vasospasm - Vasospastic angina

1

XII.ah Tachycardia

1

XII.ai Cardiotoxicity

1

XII.ba Sudden cardiac death

1

XII.bt ST segment elevation

1

XVII.b Opportunistic pulmonary/systemic infections

3

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist